期刊
FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.858480
关键词
ferroptosis; cancer cell; brain tumors; GPX4; system x(c)(-); lipid ROS; iron
类别
资金
- Fondecyt regular [1181243, 1221147]
- ANID PIA ECM-12
- Fondecyt iniciacion [11200335]
- U.S. Department of Defense [W81XWH-12-1-0341]
- Fondecyt postdoctorado [3210076]
The article summarizes the challenges and needs for the treatment of neuroblastomas and glioblastomas and introduces a new type of cell death called ferroptosis, which has potential applications in the treatment of these tumors.
Neuroblastomas are the main extracranial tumors that affect children, while glioblastomas are the most lethal brain tumors, with a median survival time of less than 12 months, and the prognosis of these tumors is poor due to multidrug resistance. Thus, the development of new therapies for the treatment of these types of tumors is urgently needed. In this context, a new type of cell death with strong antitumor potential, called ferroptosis, has recently been described. Ferroptosis is molecularly, morphologically and biochemically different from the other types of cell death described to date because it continues in the absence of classical effectors of apoptosis and does not require the necroptotic machinery. In contrast, ferroptosis has been defined as an iron-dependent form of cell death that is inhibited by glutathione peroxidase 4 (GPX4) activity. Interestingly, ferroptosis can be induced pharmacologically, with potential antitumor activity in vivo and eventual application prospects in translational medicine. Here, we summarize the main pathways of pharmacological ferroptosis induction in tumor cells known to date, along with the limitations of, perspectives on and possible applications of this in the treatment of these tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据